---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-224053"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2025-09-30T23:59:59+00:00"
generated_at: "2026-05-17T05:19:06.213472+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# enGene appoints Dr. Hussein Sweiti as CMO; former J&J bladder cancer lead

## Summary
- Dr. Sweiti appointed Chief Medical Officer effective September 29, 2025.
- Previously Global Medical Head, Oncology at J&J; led bladder cancer portfolio and recent FDA NMIBC approval.
- Will oversee global clinical development for detalimogene; BLA submission planned for 2H 2026.
- Brings 15+ years experience in surgical oncology, drug development, and regulatory submissions.
- Appointed after target enrollment reached in pivotal detalimogene NMIBC trial.

## SEC filing metadata
- accession: 0001193125-25-224053
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2025-09-30T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312525224053/0001193125-25-224053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312525224053/engn-20250930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-224053
- JSON: https://secwatch.observer/filing/0001193125-25-224053.json
- Plain text: https://secwatch.observer/filing/0001193125-25-224053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.